BR-111

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameBR-111
Drug Alias NameBR-111
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Eribulin payload
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-Inactive tyrosine-protein kinase transmembrane receptor ROR1
TargetsTubulinInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang BioRay Biopharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang BioRay Biopharmaceuticals Co LtdHisun Biopharmaceutical Co Ltd
Inactive CompaniesBioRay Pharmaceutical Co Ltd
Active IndicationsLymphoma, Large B-Cell, DiffuseNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A